Most recently as Global Project Leader for Oncology and Director of Global Project Management for Oncology, Dr. Klein was responsible for the development of a number of oncology drugs, including a signal transduction inhibitor (currently in phase III clinical development) and a novel taxane.
From 1996 to 1999, Dr. Klein managed the worldwide development of several Bayer diabetes drugs as the Director of International Project Management for Metabolics. Between 1993 and 1996, Dr. Klein served as Vice President Technical Operations and Site Manager at Bayer's California facility where he was responsible for the production of Kogenate®.
From 1991 to 1993, Dr. Klein was Head of Regulatory Affairs International with Bayer AG’s Pharmaceutical Business Group in Germany and previously served as Project Director and Research Scientist at Bayer’s Miles Inc./Cutter Biological in California.
During the first six years of his industry career, Dr. Klein was a Head of Laboratory with Bayer AG in Germany. Dr. Klein earned his Ph.D. in biochemistry from the University of Münster in Germany.
Full biographies, unique experience, expertise & accomplishments of each advisory board member:
- Neil J. Campbell,
M.A., M.B.A. – Chairman - Kevin Carroll
- Edward L. Erickson
- Daniel D'Agostino
- Nigel Gaymond, M.A.
- David M. Koeninger
- Udo Klein, Ph.D.
- Stefan Loren, Ph.D.
- Kevin Nickels
- Rick Pierce
- Robin Pratt, Ph.D.
- Linda M. Pullan, Ph.D.
- Dane Saglio, C.P.A.
- Peter G. Savas
- Chris Ward
- Ruth Williams, Esq.
Dr. Udo Klein has more than 25 years of broad-based pharmaceutical development and regulatory experience, having participated in the development of a variety of therapeutic compounds from discovery to product launch. Dr. Klein is currently head of oncology research & experimental medicines for biotechnology giant, Genentech.
Prior to joining Genentech, Dr. Klein was Senior Vice President Research and Development at CGI Pharmaceuticals, Inc. where he lead the research, discovery and clinical development of the company advancing the lead clinical candidate into the clinic.
Prior to joining CGI in October 2004, Dr. Klein was Senior Vice President Research and Development at EntreMed where he led the Company's small molecule therapeutics research and development effort and was responsible for advancing the Company’s pipeline, in particular EntreMed’s lead clinical candidate, Panzem®.
Before joining EntreMed in October 2003, Dr. Klein was with Bayer Corporation for 23 years, holding numerous senior-level management positions with the Pharmaceutical Division.
 |
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|||||||||